5 Key Takeaways

• 1

  A 487-gene expression profile test identifies atopic dermatitis patients likely to respond to JAK inhibitors over Th2-targeted biologics.

• 2

  The study developed a gene expression profile test using noninvasive skin scrapings to classify patients into two molecular subgroups.

• 3

  Patients with a JAK inhibitor–responder profile showed better disease clearance and symptom control with JAK inhibitors than Th2 therapies.

• 4

  The test employs a simple skin sampling method and standard RNA sequencing, positioning it as a potential companion diagnostic.

• 5

  Molecular stratification may streamline care by aligning therapy selection with individual patient profiles, enhancing treatment outcomes.